Andere talen Kadimastem Ltd

Aandelen

KDST

IL0011284614

Beurs gesloten - TEL AVIV STOCK EXCHANGE Andere beurzen 13:24:09 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
494,7 ^ILa	+1,33%		+7,17%	-16,58%

28/03	Kadimastem Ltd rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
28/02	IMC kondigt potentiële omgekeerde fusie aan met een toonaangevend bedrijf voor klinische celtherapie	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	28/02
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC	28/02
IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company	28/02
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.	28/02
Kadimastem Plans Listing on Nasdaq Through Merger	18/02
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq	16/02
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India	07/02
A peer reviewed article on Kadimastem's AstroRxÃ‚® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology	25/01
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA	22/01
ITolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products	07/11
Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes	07/11
Kadimastem Ltd announced that it expects to receive ILS 6.783 million in funding from Alpha Capital Anstalt and another investor	16-10-23
Kadimastem Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	31-08-23
Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes	20-06-23
Kadimastem : Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS	09-03-21
Kadimastem : Announces Executive Management Changes	01-02-21
Kadimastem : AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial	16-12-20
Kadimastem : Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS	03-08-20
Kadimastem : Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS	06-01-20

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kadimastem Ltd

Aandelen

KDST

IL0011284614

Andere talen

Filters